Physician profile
Ashwin Kumar Shankar
NPI 1467010942
$6,382.82
in general payments reported to CMS, 2019-2025
25 companies · $3,669 in 2025
The $3,669 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $473 · 2023: $947 · 2024: $1,294 · 2025: $3,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,039 · Consulting Fee: $1,719 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.37 |
| Consulting Fee | $1,719.00 |
| Education | $150.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,432.61 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,069.61 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $609.35 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $517.55 | 2024-2025 | |
| Amgen INC. | $344.24 | 2022-2025 | Tezspire |
| Csl Behring | $239.80 | 2022-2024 | Haegarda, Hizentra |
| Sanofi-Aventis U.S. LLC | $150.98 | 2024-2025 | |
| Glaxosmithkline, LLC. | $131.08 | 2023-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Biocryst US Sales Co., LLC | $115.05 | 2024-2025 | Orladeyo |
| Blueprint Medicines Corporation | $112.40 | 2023 | Ayvakit |
| Genentech USA, INC. | $102.25 | 2024 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $92.26 | 2025 | Neffy |
| Abbvie INC. | $86.49 | 2022-2024 | |
| Optinose US, INC. | $72.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.65 | 2024-2025 | Takhzyro, Hyqvia |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $38.82 | 2022-2024 | Octagam Immune Globulin (Human) |
| Pharming Healthcare, INC. | $36.46 | 2024-2025 | Ruconest |
| Kaleo, INC. | $33.57 | 2024 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $31.66 | 2022-2023 | Airduo Digihaler |
| Hikma Pharmaceuticals USA | $21.45 | 2025 | Ryaltris |
| Galderma Laboratories, L.P. | $17.70 | 2025 | Nemluvio |
| Merck Sharp & Dohme LLC | $16.29 | 2023 | |
| Grifols USA, LLC | $16.00 | 2024 | Prolastin-C Liquid |
| Organon LLC | $15.03 | 2025 | |
| Horizon Therapeutics Plc | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Shankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.